User login
Key clinical point: Valproic acid, propranolol, and venlafaxine significantly improved vestibular migraine frequency but had no significant differences in terms of vestibular migraine severity, dropout rates, and safety profiles compared with placebo.
Major finding: Compared with placebo, valproic acid (standardized mean difference [SMD] −1.61; 95% CI −2.69 to −0.54), propranolol (SMD −1.36; 95% CI −2.55 to −0.17), and venlafaxine (SMD −1.25; 95% CI −2.32 to −0.18) led to better improvement in vestibular migraine frequency. However, vestibular migraine severity, dropout rates, and safety profiles did not differ significantly between the treatment groups.
Study details: This network meta-analysis of seven randomized controlled trials included 828 patients with vestibular migraine.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Chen J-J et al. Network meta-analysis of different treatments for vestibular migraine. CNS Drugs. 2023;37(9):837-847 (Sep 7). doi: 10.1007/s40263-023-01037-0
Key clinical point: Valproic acid, propranolol, and venlafaxine significantly improved vestibular migraine frequency but had no significant differences in terms of vestibular migraine severity, dropout rates, and safety profiles compared with placebo.
Major finding: Compared with placebo, valproic acid (standardized mean difference [SMD] −1.61; 95% CI −2.69 to −0.54), propranolol (SMD −1.36; 95% CI −2.55 to −0.17), and venlafaxine (SMD −1.25; 95% CI −2.32 to −0.18) led to better improvement in vestibular migraine frequency. However, vestibular migraine severity, dropout rates, and safety profiles did not differ significantly between the treatment groups.
Study details: This network meta-analysis of seven randomized controlled trials included 828 patients with vestibular migraine.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Chen J-J et al. Network meta-analysis of different treatments for vestibular migraine. CNS Drugs. 2023;37(9):837-847 (Sep 7). doi: 10.1007/s40263-023-01037-0
Key clinical point: Valproic acid, propranolol, and venlafaxine significantly improved vestibular migraine frequency but had no significant differences in terms of vestibular migraine severity, dropout rates, and safety profiles compared with placebo.
Major finding: Compared with placebo, valproic acid (standardized mean difference [SMD] −1.61; 95% CI −2.69 to −0.54), propranolol (SMD −1.36; 95% CI −2.55 to −0.17), and venlafaxine (SMD −1.25; 95% CI −2.32 to −0.18) led to better improvement in vestibular migraine frequency. However, vestibular migraine severity, dropout rates, and safety profiles did not differ significantly between the treatment groups.
Study details: This network meta-analysis of seven randomized controlled trials included 828 patients with vestibular migraine.
Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.
Source: Chen J-J et al. Network meta-analysis of different treatments for vestibular migraine. CNS Drugs. 2023;37(9):837-847 (Sep 7). doi: 10.1007/s40263-023-01037-0